To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Intravenous thrombolysis … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Intravenous thrombolysis for suspected ischemic stroke with seizure at onset

Journal article
Authors A. A. Polymeris
S. Curtze
H. Erdur
C. Hametner
M. R. Heldner
A. E. Groot
A. Zini
Y. Bejot
A. Dietrich
N. Martinez-Majander
R. von Rennenberg
C. Gumbinger
S. Schaedelin
G. M. De Marchis
S. Thilemann
C. Traenka
P. A. Lyrer
L. H. Bonati
S. Wegener
P. A. Ringleb
Turgut Tatlisumak
C. H. Nolte
J. F. Scheitz
M. Arnold
D. Strbian
P. J. Nederkoorn
H. Gensicke
S. T. Engelter
Trisp Collaborators Trisp Collaborators
Published in Annals of Neurology
Volume 86
Issue 5
Pages 770-779
ISSN 0364-5134
Publication year 2019
Published at Institute of Neuroscience and Physiology
Pages 770-779
Language en
Keywords health-care professionals, early management, plasminogen-activator, mimics, guidelines, alteplase, safety, classification, association, population, Neurosciences & Neurology
Subject categories Nursing


Objective Seizure at onset (SaO) has been considered a relative contraindication for intravenous thrombolysis (IVT) in patients with acute ischemic stroke, although this appraisal is not evidence based. Here, we investigated the prognostic significance of SaO in patients treated with IVT for suspected ischemic stroke. Methods In this multicenter, IVT-registry-based study we assessed the association between SaO and symptomatic intracranial hemorrhage (sICH, European Cooperative Acute Stroke Study II definition), 3-month mortality, and 3-month functional outcome on the modified Rankin Scale (mRS) using unadjusted and adjusted logistic regression, coarsened exact matching, and inverse probability weighted analyses. Results Among 10,074 IVT-treated patients, 146 (1.5%) had SaO. SaO patients had significantly higher National Institutes of Health Stroke Scale score and glucose on admission, and more often female sex, prior stroke, and prior functional dependence than non-SaO patients. In unadjusted analysis, they had generally less favorable outcomes. After controlling for confounders in adjusted, matched, and weighted analyses, all associations between SaO and any of the outcomes disappeared, including sICH (odds ratio [OR](unadjusted) = 1.53 [95% confidence interval (CI) = 0.74-3.14], ORadjusted = 0.52 [95% CI = 0.13-2.16], ORmatched = 0.68 [95% CI = 0.15-3.03], ORweighted = 0.95 [95% CI = 0.39-2.32]), mortality (ORunadjusted = 1.49 [95% CI = 1.00-2.24], ORadjusted = 0.98 [95% CI = 0.5-1.92], ORmatched = 1.13 [95% CI = 0.55-2.33], ORweighted = 1.17 [95% CI = 0.73-1.88]), and functional outcome (mRS >= 3/ordinal mRS: ORunadjusted = 1.33 [95% CI = 0.96-1.84]/1.35 [95% CI = 1.01-1.81], ORadjusted = 0.78 [95% CI = 0.45-1.32]/0.78 [95% CI = 0.52-1.16], ORmatched = 0.75 [95% CI = 0.43-1.32]/0.45 [95% CI = 0.10-2.06], ORweighted = 0.87 [95% CI = 0.57-1.34]/1.00 [95% CI = 0.66-1.52]). These results were consistent regardless of whether patients had an eventual diagnosis of ischemic stroke (89/146) or stroke mimic (57/146 SaO patients). Interpretation SaO was not an independent predictor of poor prognosis. Withholding IVT from patients with assumed ischemic stroke presenting with SaO seems unjustified. ANN NEUROL 2019

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?